Haemophilus b Conjugate Vaccine
- Atc Codes:J07AG
Table of contents
- Brand Names
- Drug Combinations
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Dosage
Brand Names
Europe
Belgium: Act-Hib; Bulgaria: Act-Hib; Cyprus: Act-Hib; Czech Republic: Hiberix; France: Act-Hib; Germany: Act-Hib, Grippe-Nosode, Hiberix, HibTITER; Greece: Act-Hib, Hiberix; Ireland: Act-Hib, Hiberix; Lithuania: Hiberix; Netherlands: Act-Hib, Hiberix; Poland: Act-Hib; Portugal: Act-Hib, Hiberix; Slovakia: Act-HIB, Hiberix; Sweden: Act-HIB.
North America
Canada: Act-Hib, PedvaxHib; USA: Act-Hib, Hiberix, PedvaxHib.
Latin America
Mexico: Pedvax Hib.
Drug combinations
Haemophilus influenzae b Conjugate Vaccine and Hepatitis B virus Vaccine
Haemophilus influenzae b Conjugate Vaccine and Neisseria meningitidis group C
Haemophilus influenzae b Conjugate Vaccine, Klebsiella pneumoniae, Streptococcus pneumoniae, and Streptococcus pyogenes
Haemophilus influenzae b Conjugate Vaccine, Bordetella pertussis, Diphtheria Toxoid, Pertactin, and Tetanus Toxoid
Haemophilus influenzae b Conjugate Vaccine, Klebsiella ozaenae, K. pneumoniae, Neisseria catarrhalis, Pneumococcus, Staphylococcus, and Streptococcus
Haemophilus influenzae b Conjugate Vaccine, Gaffyka tetragena, Klebsiella pneumoniae, Moraxella spp., Neisseria catarrhalis, Staphylococcus aureus, S. pyogenes, and Streptococcus pneumoniae
Haemophilus influenzae b Conjugate Vaccine, Bordetella pertussis, Diphtheria Toxoid, Tetanus Toxoid, Hepatitis B surface Antigen (HbsAg), Pertactin, Poliovirus type 1 (Mahoney), Poliovirus type 2 (MEF 1), and Poliovirus type 3 (Saukett)
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Vaccines. Inactivated Bacterial Vaccine. (ATC-Code: J07AG).
Mechanism of action
Stimulates production of antibodies against capsular antigens and provides active immunity to Haemophilus influenzae type b.
Therapeutic use
Routine immunization of children 2 months to 5 years of age against invasive disease caused by H. influenzae type b.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to Haemophilus b polysaccharide vaccine or any component of the formulation.
Warnings and precautions
Anaphylactoid/hypersensitivity reactions. Immunization should be delayed during the course of acute febrile illness. Use with caution in history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy. Use with caution in severely immunocompromised patients (e.g. patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high-dose corticosteroids)). May be used in patients with HIV infection.